table td { font-size: 16px !important; }
Category

NASH

Graviton
9
NASH
11/2021

Novel, first-in-class, fatty acid synthase (FASN) inhibitor TVB-2640 demonstrates robust clinical efficacy and safety in a global phase 2 randomized placebo-controlled NASH trial (FASCINATE-1) conducted in the U.S. and China

AASLD The Liver Meeting
Read More
Graviton
9
NASH
09/2021

Translation of FASN Inhibitor TVB-2640 from Preclinical MOA to Clinical POC in NASH

NASH and Fibrosis Conference
Read More
Graviton
9
NASH
07/2021

TVB-2640 (FASN inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled Ph2a trial

Gastroenterology
Read More
Graviton
9
NASH
06/2021

Analysis of non-invasive biomarker tests in the Phase 2 FASCINATE-1 study of FASN inhibitor TVB-2640

EASL International Liver Congress
Read More
Graviton
9
NASH
11/2020

Novel, first-in-class, fatty acid synthase inhibitor, TVB-2640 versus placebo demonstrates clinically significant reduction in liver fat by MRI-PDFF in NASH

AASLD
Read More
Graviton
9
brain_imagination-2560x1440
NASH
08/2020

Novel, first-in-class, fatty acid synthase inhibitor, TVB-2640 versus placebo demonstrates clinically significant reduction in liver fat by MRI-PDFF in NASH

EASL International Liver Congress
Read More
Graviton
9
NASH
08/2020

The FASN inhibitor TVB-2640 is efficacious in a new 3D human liver microtissue model of NASH

EASL International Liver Congress
Read More
Graviton
9
NASH
07/2020

Fatty Acid Synthase Inhibitor TVB-2640 Reduces Hepatic de Novo Lipogenesis in Males With Metabolic Abnormalities

Hepatology 2020
Read More
Graviton
8
NASH
11/2018

Fibroblast Growth Factor-21 and its Relationship to Human Liver Fat Synthesis; Impact of a New Therapeutic Agent

ObesityWeek
Read More